Mechanisms of tissue damage in arthritis (Q38248430)

1 September 2017

1 reference

title

Mechanisms of tissue damage in arthritis (English)

1 reference

1 September 2017

3

Josef S Smolen

1 reference

1 September 2017

Stephan Blüml

1

1 reference

1 September 2017

Kurt Redlich

series ordinal

2

1 reference

1 September 2017

publication date

12 September 2014

1 reference

Seminars in Immunopathology

1 September 2017

published in

1 reference

1 September 2017

volume

36

1 reference

1 September 2017

issue

5

1 reference

1 September 2017

page(s)

531-540

1 reference

New insights in the mechanism of bone loss in arthritis

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The links between joint damage and disability in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Current perspectives on synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Epigenetic modifications in rheumatoid arthritis, a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Genetic regulation of osteoclast development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Role of NF-κB in the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Sphingosine 1-phosphate counteracts the effects of interleukin-1β in human chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Epigenetic regulation of dendritic cell differentiation and function by oxidized phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

TNF-induced structural joint damage is mediated by IL-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Cadherin-11 in synovial lining formation and pathology in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The SCID mouse model: novel therapeutic targets - lessons from gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Cartilage homeostasis in health and rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Proteinases in the joint: clinical relevance of proteinases in joint destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Toward a refined definition of monocyte subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

T-cells in the pathogenesis of rheumatoid arthritis villains or accomplices?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

CD4 T cells: fates, functions, and faults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Mobilization of natural killer cells inhibits development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

B-cell targeted therapeutics in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

B cells in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Innate immune processes in lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Alternative p38 MAPKs are essential for collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Janus kinase inhibitors in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

PTEN function: how normal cells control it and tumour cells lose it

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

NF-κB as a target for modulating inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The complexity of NF-κB signaling in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Bortezomib attenuates murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The TSC-mTOR signaling pathway regulates the innate inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Update on Wnt signaling in bone cell biology and bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Targeting TNF receptors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interleukin 6 plays a key role in the development of antigen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interleukin-6: discovery of a pleiotropic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Critical regulation of early Th17 cell differentiation by interleukin-1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

SHIP1 Negatively Regulates Proliferation of Osteoclast Precursors via Akt-Dependent Alterations in D-Type Cyclins and p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Bone and haematopoietic defects in mice lacking c-fos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0442-8

Oxidized Phospholipids Negatively Regulate Dendritic Cell Maturation Induced by TLRs and CD40

21 January 2018

1 reference

12 December 2020

Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells

1 reference

12 December 2020

Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production

1 reference

12 December 2020

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

1 reference

12 December 2020

A randomized, double‐blind, placebo‐controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis

1 reference

12 December 2020

Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

1 reference

12 December 2020

Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction

1 reference

12 December 2020

Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis

1 reference

12 December 2020

Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1

1 reference

12 December 2020

CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis

1 reference

12 December 2020

IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

1 reference

12 December 2020

Organ-specific disease provoked by systemic autoimmunity

1 reference

12 December 2020

Dynamic visualization of RANKL and Th17-mediated osteoclast function.

1 reference

12 December 2020

Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis

1 reference

12 December 2020

Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines.

1 reference

12 December 2020

mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis

1 reference

12 December 2020

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

1 reference

12 December 2020

Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

1 reference

12 December 2020

Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis

1 reference

12 December 2020

Phosphatidylinositol 3-kinase: the oncoprotein

1 reference

12 December 2020

Joint damage and disability in rheumatoid arthritis: an updated systematic review

1 reference

12 December 2020

Epidemiology and burden of illness of rheumatoid arthritis

1 reference

12 December 2020

Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function

1 reference

12 December 2020

The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population

1 reference

12 December 2020

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

1 reference

12 December 2020

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

12 December 2020

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

1 reference

12 December 2020

Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro

1 reference

12 December 2020

Dickkopf-1 is a master regulator of joint remodeling

1 reference

12 December 2020

Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis

1 reference

12 December 2020

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid

1 reference

12 December 2020

Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies

1 reference

12 December 2020

10.1007/S00281-014-0442-8

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1026414027

0 references

1 reference